

# Alessandro Loglio

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1447994/alessandro-loglio-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

732  
citations

11  
h-index

26  
g-index

60  
ext. papers

1,030  
ext. citations

4  
avg, IF

3.79  
L-index

#	Paper	IF	Citations
31	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , <b>2017</b> , 66, 1444-1453	11.2	180
30	Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 615-625	13.4	117
29	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1129-1136	13.4	64
28	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1118-25	13.4	56
27	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1088-1096	13.4	50
26	Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 45-51	7.9	37
25	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1037-1045	13.4	34
24	Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 834-839	13.4	30
23	Treatment of hepatitis B: Is there still a role for interferon?. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 79-83	7.9	23
22	The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. <i>Liver International</i> , <b>2020</b> , 40, 1987-1996	7.9	18
21	Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	15
20	Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2018</b> , 16, 153-161	5.5	11
19	Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. <i>Cell Reports Medicine</i> , <b>2020</b> , 1, 100060	18	10
18	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 783-793	13.4	9
17	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , <b>2019</b> , 39, 484-493	7.9	8
16	A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 564-573	6.1	8
15	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1969-1979	11.6	7

14	IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , <b>2018</b> , 38, 417-423	7.9	7
13	Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , <b>2019</b> , 39, 1964-1974	7.9	7
12	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1164-1169	3.3	6
11	Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 431-439 <sup>1</sup>	6.1	6
10	Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. <i>Haematologica</i> , <b>2017</b> , 102, e423-e426	6.6	5
9	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 419-424	3.3	4
8	Safety and effectiveness of up to 3 years bulevirtide monotherapy in patients with HDV-related cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
7	SAT-130-Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e687-e688	13.4	2
6	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 733-744	6.1	2
5	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	2
4	Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 464-474	3.4	1
3	Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. <i>Current Hepatology Reports</i> , <b>2018</b> , 17, 502-510	1	1
2	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , <b>2021</b> , 3, 100290	10.3	0
1	Novel Therapies That May Cure Chronic Hepatitis B Virus. <i>Clinics in Liver Disease</i> , <b>2021</b> , 25, 875-899	4.6	0